Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Laikon General District Hospital, Athens |
---|---|
Information provided by: | Laikon General District Hospital, Athens |
ClinicalTrials.gov Identifier: | NCT00483925 |
Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and hypopituitarism, conditions associated with increased risk of cardiovascular diseases.
Objective: To investigate glucose and lipid metabolism, insulin resistance, structural arterial and functional endothelial properties in patients with multisystem LCH in a prospective, observational study.
Interventions:Cardiovascular risk factors: arterial blood pressure, lipid profile, mathematical indices of insulin resistance (IR), intima media thickness, brachial artery flow mediated dilatation, dynamic indices of IR, pituitary function and C-reactive protein will be estimated in patients with LCH and in a control group matched for gender, age, BMI and smoking habits.
Condition |
---|
Histiocytosis, Langerhans-Cell |
Study Type: | Observational |
Study Design: | Screening, Longitudinal, Case Control, Prospective Study |
Official Title: | CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Gregory Kaltsas, MD, FRCP | 00302107462657 | gkaltsas@endo.gr |
Greece | |
Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital, | Recruiting |
Athens, Greece, 11527 | |
Contact: Gregory Kaltsas, MD, FRCP | |
Principal Investigator: Krystallenia I Alexandraki, MD, MSc, PhD |
Study Director: | Gregory Kaltsas, MD, FRCP | Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital |
Study ID Numbers: | ES 511 |
Study First Received: | June 6, 2007 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00483925 |
Health Authority: | Greece: Ethics Committee |
Langerhans cell histiocytosis flow mediated dilatation intima media thickness insulin resistance |
hypopituitarism glucose and lipid metabolism, structural arterial and functional endothelial properties in patients with multisystem LCH |
Lung Diseases, Interstitial Dilatation, Pathologic Langerhans cell histiocytosis Histiocytosis, Langerhans-Cell Insulin Histiocytosis X Lymphatic Diseases |
Letterer-Siwe disease Hypopituitarism Histiocytosis Respiratory Tract Diseases Lung Diseases Insulin Resistance Congenital Abnormalities |
Reticuloendotheliosis |